Korro Bio Inc. Company Profile
NASDAQ: KRROHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Korro Bio at a glance
Korro Bio Inc. (NASDAQ: KRRO) is a Biotechnology company in the Healthcare sector headquartered in Cambridge, MA. Korro Bio is led by Dr. Ram Aiyar MBA, Ph.D. and employs about 57 people. The company's shares have traded publicly since 2019.
At a market capitalization of $154.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001703647, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Korro Bio do?
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Korro Bio Inc.
- Ticker
- NASDAQ: KRRO
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Ram Aiyar MBA, Ph.D.
- Employees
- 57
- Headquarters
- 60 First Street, Cambridge, MA, United States
- Phone
- 617 468 1999
- Website
- korrobio.com
- IPO year
- 2019
- Market cap
- $154.47M
- SEC CIK
- 0001703647
Companies similar to Korro Bio
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CDXSCodexis Inc. | 1.41 | +3.68% | $154.40M | vs KRRO |
| TARAProtara Therapeutics Inc. | 2.59 | +1.37% | $153.06M | vs KRRO |
| CHRSCoherus Oncology Inc. | 1.01 | -1.94% | $156.05M | vs KRRO |
| NERVMinerva Neurosciences Inc | 3.27 | -4.66% | $156.13M | vs KRRO |
| ALXOALX Oncology Holdings Inc. | 1.13 | +1.80% | $156.25M | vs KRRO |
| MENSJyong Biotech Ltd. | 2.06 | +1.98% | $156.62M | vs KRRO |
| VYGRVoyager Therapeutics Inc. | 2.47 | +0.41% | $152.20M | vs KRRO |
| ABOSAcumen Pharmaceuticals Inc. | 2.10 | +3.45% | $151.87M | vs KRRO |